- Home
- ADC vs PODD Comparison
ADC vs PODD Comparison
Compare ADC & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADC | PODD |
|---|---|---|
| Founded | 1971 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 10.2B |
| IPO Year | 1996 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ADC | PODD |
|---|---|---|
| Price | $65.31 | $131.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 25 |
| Target Price | $83.83 | ★ $171.91 |
| AVG Volume (30 Days) | ★ 1.3M | 1.2M |
| Earning Date | 10-20-2026 | 11-04-2026 |
| Dividend Yield | ★ 4.80% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.94 | ★ 2.67 |
| Revenue | $718,398,000.00 | ★ $2,708,100,000.00 |
| Revenue This Year | $17.40 | $21.38 |
| Revenue Next Year | $12.78 | $13.78 |
| P/E Ratio | $71.97 | ★ $49.26 |
| Revenue Growth | 16.42 | ★ 30.73 |
| 52 Week Low | $66.50 | $126.40 |
| 52 Week High | $82.08 | $354.88 |
Technical Indicators
Market Signals| Indicator | ADC | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 18.37 | 35.96 |
| Support Level | N/A | $131.24 |
| Resistance Level | $81.89 | $153.33 |
| Average True Range (ATR) | 1.12 | 3.84 |
| MACD | -0.04 | -0.44 |
| Stochastic Oscillator | 1.45 | 12.17 |
Price Performance
Historical ComparisonAbout ADC Agree Realty Corporation
Agree Realty Corporation operates as a fully integrated real estate investment trust mainly focused on the ownership, acquisition, development and management of retail properties net leased to industry-tenants. The Company is mainly in the business of acquiring, developing and managing retail real estate. Some of its properties in the portfolio include Walmart, 7-Eleven, Wawa, Gerber Collision and others.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.